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Abstract
Background
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease world-
wide. Many individuals have risk factors associated with NAFLD, but the majority do not
develop advanced liver disease: cirrhosis, hepatic decompensation, or hepatocellular carci-
noma. Identifying people at high risk of experiencing these complications is important in
order to prevent disease progression. This review synthesises the evidence on metabolic
risk factors and their potential to predict liver disease outcomes in the general population at
risk of NAFLD or with diagnosed NAFLD.
Methods and findings
We conducted a systematic review and meta-analysis of population-based cohort studies.
Databases (including MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov)
were searched up to 9 January 2020. Studies were included that reported severe liver dis-
ease outcomes (defined as liver cirrhosis, complications of cirrhosis, or liver-related death)
or advanced fibrosis/non-alcoholic steatohepatitis (NASH) in adult individuals with metabolic
risk factors, compared with individuals with no metabolic risk factors. Cohorts selected on
the basis of a clinically indicated liver biopsy were excluded to better reflect general popula-
tion risk. Risk of bias was assessed using the QUIPS tool. The results of similar studies
were pooled, and overall estimates of hazard ratio (HR) were obtained using random-effects
meta-analyses. Of 7,300 unique citations, 22 studies met the inclusion criteria and were of
sufficient quality, with 18 studies contributing data suitable for pooling in 2 random-effects
meta-analyses. Type 2 diabetes mellitus (T2DM) was associated with an increased risk of
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incident severe liver disease events (adjusted HR 2.25, 95% CI 1.83–2.76, p < 0.001, I2
99%). T2DM data were from 12 studies, with 22.8 million individuals followed up for a
median of 10 years (IQR 6.4 to 16.9) experiencing 72,792 liver events. Fourteen studies
were included in the meta-analysis of obesity (BMI > 30 kg/m2) as a prognostic factor, pro-
viding data on 19.3 million individuals followed up for a median of 13.8 years (IQR 9.0 to
19.8) experiencing 49,541 liver events. Obesity was associated with a modest increase in
risk of incident severe liver disease outcomes (adjusted HR 1.20, 95% CI 1.12–1.28, p <
0.001, I2 87%). There was also evidence to suggest that lipid abnormalities (low high-density
lipoprotein and high triglycerides) and hypertension were both independently associated
with incident severe liver disease. Significant study heterogeneity observed in the meta-
analyses and possible under-publishing of smaller negative studies are acknowledged to be
limitations, as well as the potential effect of competing risks on outcome.
Conclusions
In this review, we observed that T2DM is associated with a greater than 2-fold increase in
the risk of developing severe liver disease. As the incidence of diabetes and obesity con-
tinue to rise, using these findings to improve case finding for people at high risk of liver dis-
ease will allow for effective management to help address the increasing morbidity and
mortality from liver disease.
Trial registration
PROSPERO CRD42018115459.
Author summary
Why was this study done?
• This review gathered together the existing evidence on which metabolic risk factors are
most associated with severe forms of liver disease.
• Many people have risk factors for developing fat on their livers, but most will not
develop severe liver disease.
• Knowing which individuals are at greatest risk of liver disease will facilitate targeting of
interventions to people with the greatest potential to benefit.
What did the researchers do and find?
• Combining the results of many individual studies, we found that type 2 diabetes was
associated with a more than 2-fold increase in the likelihood of developing severe liver
disease.
• Other metabolic risk factors (obesity, fat levels in the blood, and high blood pressure)
were also reviewed. Obesity was also associated with an increased risk of liver disease,
but to a lesser extent than type 2 diabetes.
• There was less information available on the other risk factors.
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What do these findings mean?
• These findings mean that when health professionals are trying to find people at high
risk of significant metabolic liver disease, they should focus on those who already have
diabetes.
• The relative lack of evidence on the effects of other metabolic risk factors and combina-
tions of these risk factors in predicting liver disease should be a focus of research in the
future.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease world-
wide, with an estimated population prevalence rate of up to 30% in Europe [1]. Progressive
liver disease is asymptomatic and usually diagnosed late, at the stage of decompensated cirrho-
sis, when intervention is less effective and mortality rates are high. Most people with NAFLD
will not develop progressive disease (advanced fibrosis/cirrhosis), but recent guidelines have
stressed the importance of identifying the minority that will [2]. Data from biopsy studies have
shown that the histological staging of liver fibrosis is one of the most important prognostic fac-
tors in NAFLD. Advanced fibrosis is associated with severe liver-related outcomes and
increased mortality [3,4]. Without undertaking a biopsy, advanced liver disease can be ruled
out with acceptable accuracy using non-invasive biomarkers or simple clinical scores [5,6].
However, validation of these methods in unselected populations is limited. Furthermore, in
settings where the pretest probability of advanced fibrosis is low, the positive predictive value
of non-invasive tests will fall and lead to many false positives [7]. This highlights a need to
clearly define the at-risk population before employing these tests.
Case finding for advanced liver disease amongst adults with type 2 diabetes mellitus
(T2DM) or metabolic syndrome is recommended by the European Association for the Study
of the Liver (for those aged over 50 years) and the American Diabetes Association [2,8]. Ongo-
ing studies are providing evidence for the clinical effectiveness and cost-effectiveness of risk-
factor-based case finding for NAFLD in unselected populations [9–11]. However, the high and
rising prevalence of risk factors for NAFLD means that the introduction of such programmes
at scale will be costly, and neither the UK National Institute for Health and Care Excellence
(NICE) nor the American Association for the Study of Liver Diseases has recommended case
finding in primary care in their latest NAFLD guidelines [12,13]. In the absence of proactive
case finding and assessment of high-risk individuals, case ascertainment is inconsistent and
largely opportunistic, based on chance findings of abnormal blood tests or imaging carried out
for other purposes. The current approach will not identify those at most risk. In many care set-
tings, this means diagnosis late in the disease natural history, with limited scope for effective
intervention [14].
In order to develop community-based strategies for earlier, targeted detection of liver dis-
ease, a good understanding is needed of which metabolic risk factors best predict severe
NAFLD outcomes and advanced fibrosis. Research evidence published up until 2015 was
synthesised to underpin the UK NICE guidelines [12], and this synthesis highlighted a paucity
of evidence. Since then, several studies from large population cohorts have been published. In
addition, the NICE review did not include all relevant outcomes. Cirrhosis and liver-related
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mortality outcomes were omitted, though natural history studies suggest that it is reasonable
to assume that people who develop liver cirrhosis or die from liver disease will have passed
through the stage of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis. To
address this gap in our understanding, we conducted an updated systematic review of pub-
lished observational studies including all relevant outcomes. The aim was to synthesise evi-
dence on which of the metabolic risk factors, or combination of risk factors, can best predict
incident severe liver disease outcomes or NASH/advanced fibrosis in the general population at
risk of NAFLD or with diagnosed NAFLD.
Methods
Registration of review protocol
The protocol for this review was registered in advance with PROSPERO (International Pro-
spective Register of Systematic Reviews; CRD42018115459).
Types of studies and inclusion and exclusion criteria
Original studies were included if they were observational, prospective, or retrospective studies
that reported either (1) severe liver disease outcomes (cirrhosis, complications of cirrhosis, or
liver-related death) or (2) NASH/advanced fibrosis in adults (�18 years old) with metabolic
risk factors as compared with adult individuals without metabolic risk factors. Metabolic risk
factors were defined as those included in the National Cholesterol Education Program Adult
Treatment Panel III (NCEP ATP III) definition [15], with the addition of BMI > 30 kg/m2 as
the most commonly measured obesity marker, assessed as individual risk factors or in combi-
nation, making up the metabolic syndrome.
We included both (1) studies where the cohort population had been predefined as having a
diagnosis of NAFLD (based on ultrasound, coding, or abnormal liver blood tests in the
absence of other diagnosed liver pathology) and (2) studies of general populations, if partici-
pants with risk factors for, or confirmed pathology from, alcohol, viral, or other liver disease
were excluded or adjusted for.
The following types of studies were excluded: (1) studies where entry into the cohort was
based on a tertiary referral and biopsy for clinical assessment of liver disease; (2) studies assess-
ing only hepatocellular carcinoma as an outcome in the context of a non-cirrhotic liver; (3)
studies using simple steatosis as an outcome; (4) studies performed in patients who had
received liver transplants or were undergoing bariatric surgery; (5) studies where patients
already had severe liver disease (as defined above) or NASH/advanced fibrosis at the time of
cohort entry; and (6) studies that did not specifically report any odds ratio or hazard ratio
(HR) with 95% CI for the outcome measure of interest.
We performed a systematic review following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [16] (see attached checklist [S1 Table]).
Search strategy and data extraction
Potentially relevant studies were identified through systematic literature searches of relevant
databases (MEDLINE, EMBASE, the Cochrane Library, ClinicalTrials.gov, Conference Pro-
ceedings Citation Index–Science [CPCI-S; Web of Knowledge], and OpenGrey [http://www.
opengrey.eu/]) in December 2018. No date or language restrictions were applied. Reference
lists from potentially relevant papers and previous review articles were hand searched. MeSH
(Medical Subject Headings) and free text terms for the metabolic risk factors and liver
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outcomes of interest were used. The MEDLINE search strategy is available in S2 Table.
Searches were updated in May 2019 and January 2020.
Two researchers (HJ and either GS or DS) independently screened titles and abstracts. Any
disagreement in full-text selection was resolved by consensus. Record screening was also assis-
ted by Rayyan, an online software tool that assesses similarities between selected records and
highlights other potentially relevant studies based on the screener’s previous selection [17].
Full texts of potentially relevant papers were obtained and read by 2 independent researchers
with reference to the predefined set of criteria to determine final study inclusion. Data were
extracted into a standardised, pre-piloted extraction form developed in Excel. For all studies,
we extracted information on study design, source of data, prognostic factors of interest, out-
comes of interest, and adjustment factors. Data extraction—undertaken by one researcher and
checked by a second—was based on the updated Critical Appraisal and Data Extraction for
Systematic Reviews of Prediction Modelling Studies checklist for prognostic studies
(CHARMS-PF) [18].
Assessment of risk of bias
Two authors (HJ and RB) assessed the risk of bias independently. Since the included studies
were observational cohort studies of prognostic factors, the QUIPS (Quality in Prognosis Stud-
ies) tool was used [18]. The QUIPS tool allows for quality assessment in 6 domains: study par-
ticipation, study attrition, prognostic factor measurement, outcome measurement, adjustment
for other prognostic factors, and statistical analysis/reporting. Risk of bias rating is reported as
low, moderate, or high for each domain and then an overall risk of bias assigned based on the
ratings in each domain. Any discrepancies in rating were addressed by a joint re-evaluation
with a third author.
Data synthesis and analysis
The outcome measure for the meta-analysis was incident fatal and/or non-fatal severe liver dis-
ease in individuals with metabolic risk factors, in comparison with individuals without meta-
bolic risk factors. The effect measures reported in the included studies were all HRs. The
results of the studies were pooled, and an overall estimate of HR was obtained using a ran-
dom-effects model. This model takes into account study heterogeneity, which was felt to be
necessary from assessment of the clinical heterogeneity of the studies during data extraction,
as well as the statistical heterogeneity as measured by the I2 statistic. Where authors reported
HRs for subgroups, a fixed-effects meta-analysis was first performed so a summary (pooled)
HR could be included in the overall analysis. Publication bias was evaluated using visual
inspection of funnel plots. Meta-analysis was carried out using Review Manager 5.3,
Cochrane’s meta-analysis software [19]. The prognostic factors with sufficient data and homo-
geneity between studies to carry out meta-analysis were T2DM and obesity (as measured by
BMI). For each of these prognostic factors, severe liver disease outcomes were stratified into
liver disease mortality, non-fatal severe liver disease events (cirrhosis and complications of cir-
rhosis), and a combined endpoint of both. Pre-specified sensitivity analyses were carried out
to examine effect sizes when limiting the analysis to the following subgroups of studies: studies
of participants with risk factors taken from a population with no previous diagnosis of NAFLD
and studies with a low risk of bias as measured by the QUIPS tool. A narrative synthesis was
conducted to expand on obesity as a prognostic factor of interest beyond BMI, and to summa-
rise the evidence on the role of hypertension and lipid abnormalities in predicting advanced
liver outcomes, as well as the evidence around combinations of metabolic risk factors for prog-
nosticating advanced liver disease outcomes.
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Patient and public involvement
An expert patient and public involvement group, including patients with late diagnosed
NAFLD, were involved in the design of this review. They have had no role in the conduct or
reporting of this review but will be actively involved in dissemination of the results to regional
and national patient support groups.
Results
The searches identified 7,300 unique citations. Of the titles and abstracts screened, 267 articles
were selected for full-text screening, where 245 were excluded for reasons reported in the
PRISMA diagram (Fig 1). A total of 22 unique studies representing data from 16 cohorts were
eligible for inclusion in the systematic review, and were assessed for quality [20–41]. Studies
using data from the same cohort were only included if the sub-studies were assessing different
prognostic metabolic factors.
Characteristics of included studies
Studies were included from Europe (Sweden [21,22,26–28,33,37,38], UK [20,32], Italy [20],
Netherlands [20], and Spain [20]), North America (US [23,25,29–31,34,39–41] and Canada
[36]), and Asia (Singapore [24] and China [35]), with data on over 24 million individuals. All
the eligible studies were prospective or retrospective cohorts in design, and were all commu-
nity-based general population cohorts, some defined by data linkage. In 16 of the studies, rep-
resenting 12 of the cohorts, the included population was not pre-selected on the basis of a
diagnosis of NAFLD, and liver-related outcomes were presumed to represent outcomes from
severe NAFLD, as participants with evidence of other common causes of liver disease were
either excluded at cohort entry or adjusted for in the analysis. All of the included studies
excluded individuals drinking alcohol at harmful levels and those with alcohol-related liver
disease at cohort entry, or adjusted for alcohol consumption during analysis. In 6 of the stud-
ies, representing 4 of the cohorts, part of the population under study had a predefined diagno-
sis of NAFLD, defined using ultrasound, abnormal liver blood tests, or International
Classification of Diseases (ICD) coding at the time of cohort entry [20,25,31,38–40]. In 8 of the
studies, the cohort studied included only men or women, but was otherwise an approximately
general population. Thirteen of the studies looked at T2DM as a prognostic factor of interest,
14 looked at BMI, and 4 were interested in other measures of central obesity. Fewer studies
assessed the effects of dyslipidaemia and hypertension as individual metabolic risk factors,
with heterogeneity in prognostic factor definition and outcome of interest. Metabolic syn-
drome as a risk factor was studied in 4 studies, with 3 of them based on sub-cohorts from the
same population cohort [25,39,40]. Of the 22 studies, 5 employed liver disease mortality as an
outcome measure, 11 fatal and non-fatal severe liver disease events (combined endpoint), and
6 non-fatal severe liver disease events (cirrhosis/complications of cirrhosis). None of the
included studies reported NASH/advanced fibrosis as outcome measures although these were
included in the search strategy. Liver disease events were validated in all the studies by medical
records and death certificates using ICD diagnosis codes. Of the 22 included studies, 13
received a low risk of bias rating using the QUIPS tool (S3 Table). Further details of included
studies are shown in Table 1.
T2DM and the risk of incident severe liver disease events
Twelve studies were included in the meta-analysis of T2DM as a prognostic factor for incident
severe liver disease. One study included in the review was excluded from the pooled primary
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Fig 1. PRISMA diagram of study selection.
https://doi.org/10.1371/journal.pmed.1003100.g001
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Table 1. Characteristics of included studies.
Study Country Study design and
population
Years of
follow-
up
Diagnosis of
NAFLD at
cohort
inclusion
Metabolic
RFs studied
Study outcomes
of interest and
number of events
Adjustments of
interest
considered
Adjusted HRs for
liver events with 95%
CIs and p-values
Risk
of
bias
Alexander
2019 [20]
UK,
Netherlands,
Italy, Spain
Retrospective data
linkage cohort
analysis, 18 million,
136,703 with
NAFLD, mean age
55.8 years, 52% M
3.3 Yes (coding) T2DM, BP,
obesity
Cirrhosis/
complications,
7,375 events
Alcohol, other
metabolic RFs
�BMI > 30: 1.03
(1.03–1.04), p< 0.001;
T2DM: 2.86 (2.71–
3.02), p< 0.001; high
BP: 1.06 (1.00–1.12), p
= 0.03
Low
Andreasson
2017 [21]
Sweden
(Malmo
cohort)
Prospective
population cohort,
27,617, mean age
58.1 years, 38.8% M
19.8 No (exclusion
of other causes
of LD)
Obesity Composite non-
fatal and fatal LD,
505 events
Alcohol �BMI > 30: 1.52
(1.17–1.98), p = 0.002;
increased WC:
women: 1.75 (1.32–
2.33), p< 0.001, men:
1.69 (1.28–2.23), p<
0.001; increased
WHR: women: 1.68
(1.36–2.07), p< 0.001,
men: 1.78 (1.41–2.25),
p< 0.001
Low
Bjo¨rkstro¨m
2019 [22]
Sweden Retrospective data
linkage cohort
analysis, 2.5
million, 406,770
with T2DM, mean
age 64.7 years,
53.8% M
7.7 No (exclusion
of other causes
of LD)
T2DM Composite non-
fatal and fatal LD,
16,711 events
Unclear—high
alcohol risk
excluded at
baseline
T2DM: 2.28 (2.21–
2.36), p< 0.001
Low
El-Serag
2004 [23]
US Retrospective data
linkage cohort
analysis, 173,643
with diabetes,
650,620 without
diabetes, age > 20
years, 98% M
(veterans)
10 No (exclusion
of other causes
of LD)
T2DM Composite non-
fatal and fatal LD,
7,799 events
Alcohol T2DM: 2.15 (2.00–
2.31), p< 0.001
Mod
Goh 2017
[24]
Singapore
(Singapore
Chinese
Health Study)
Prospective
population cohort,
63,247, age 45–74
years, 50% M
16.9 No (exclusion
of other causes
of LD)
T2DM,
obesity
LD mortality, 133
events
Alcohol T2DM: 2.6 (1.73–
3.89), p< 0.001;
BMI > 30: 1.36 (0.86–
2.17), p = 0.19
Low
Golabi 2018
[25]
US (NHANES
III)
Prospective
population cohort,
3,613, median age
43 years, 50% M
19 Yes
(ultrasound)
Metabolic
syndrome
LD mortality, 22
events
Alcohol 1 MS RF: 26.35 (2.46–
282.72), p = 0.007; 2
MS RF: 16.95 (1.59–
180.91), p = 0.019; 3
MS RF: 1.98 (0.11–
34.38), p = 0.64; 4 MS
RF: 4.57 (0.32–64.88),
p = 0.26
Mod
Hagstro¨m
2016$ [26]
Sweden Prospective
population cohort,
44,248, age 18–20
years, 100% M
(army conscripts)
37.8 No (exclusion
of other causes
of LD)
Obesity Composite non-
fatal and fatal LD,
393 events
Alcohol, BP BMI > 30: 1.59 (0.64–
3.95), p = 0.32
Mod
Hagstro¨m
2018 [27]
Sweden Prospective
population cohort,
1,220,2161, age 17–
19 years, 100% M
(army conscripts)
28.5 No (exclusion
of other causes
of LD)
Obesity,
T2DM
Composite non-
fatal and fatal LD,
5,281 events
High alcohol risk
excluded at
baseline, obesity,
BP
T2DM: 3.49 (3.01–
4.03), p< 0.001
Low
(Continued)
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Table 1. (Continued)
Study Country Study design and
population
Years of
follow-
up
Diagnosis of
NAFLD at
cohort
inclusion
Metabolic
RFs studied
Study outcomes
of interest and
number of events
Adjustments of
interest
considered
Adjusted HRs for
liver events with 95%
CIs and p-values
Risk
of
bias
Hagstro¨m
2019 [28]
Sweden Retrospective data
linkage cohort
analysis, 1,185,733,
mean age 28.6
years, 100% F
(antenatal)
13.8 No (sensitivity
analysis to
exclude alcohol
diagnoses)
Obesity,
T2DM
Composite non-
fatal and fatal LD,
852 events
Obesity, T2DM BMI > 30: 1.76 (1.27–
2.46), p = 0.001;
T2DM: 4.30 (3.23–
5.72), p< 0.001
Low
Ioannou
2003 [29]
US (NHANES
I)
Prospective
population cohort,
11,465, age 25–74
years, 50% M
13 No (exclusion
of cirrhosis
from other
causes of LD)
Obesity Composite non-
fatal and fatal LD,
89 events
T2DM,
cholesterol,
alcohol
BMI > 30: 1.65 (0.9–
3.1), p = 0.11
Low
Ioannou
2005 [30]
US (NHANES
I)
Prospective
population cohort,
11,434, age 25–74
years, 50% M
13 No (exclusion
of cirrhosis
from other
causes of LD)
Obesity
(central)
Composite non-
fatal and fatal LD,
88 events
Alcohol BMI > 30 and
subscapular-to-triceps
skinfold thickness
ratio: high: 2.2 (1.1–
4.6), p = 0.026, low:
0.8 (0.2–2.8), p = 0.75
Low
Kanwal 2019
[31]
US Retrospective data
linkage cohort
analysis, 271,906,
mean age 55.5
years, 94.3% M
9 Yes (abnormal
blood tests)
(exclusion of
other causes of
LD)
All
metabolic
risk factors
Cirrhosis, 22,794
events
Alcohol risk
excluded at
baseline and
throughout
follow-up period,
other metabolic
RFs
BMI > 30: 1.09 (1.06–
1.13), p< 0.001;
T2DM: 1.31 (1.27–
1.34), p< 0.001; high
BP: 1.59 (1.51–1.69), p
< 0.001;
dyslipidaemia
(composite): 1.23
(1.19–1.28), p< 0.001;
2 MS RF: 1.33 (1.26–
1.40), p< 0.001; 3 MS
RF: 1.61 (1.53–1.69), p
< 0.001; 4 MS RF:
2.03 (1.93–2.13), p<
0.001
Low
Liu 2010
[32]
UK (Million
Women
Study)
Prospective
population cohort,
1,230,662, mean age
56 years, 100% F
6.2 No (exclusion
of other causes
of LD)
Obesity Composite non-
fatal and fatal LD,
1,811 events
Alcohol, BMI,
T2DM
BMI > 30: 1.49 (1.33–
1.68), p< 0.001;
T2DM: 4.29 (2.74–
6.73), p< 0.001
Low
Nderitu
2017 [33]
Sweden
(AMORIS
cohort)
Prospective
population cohort,
509,436, mean age
44 years, 53.4% M
20 No (exclusion
of other causes
of LD)
All
metabolic
risk factors
Cirrhosis/
complications,
2,775 events
Other metabolic
RFs
low HDL: 1.28 (1.04–
1.59), p = 0.020; high
triglycerides: 1.30
(0.99–1.72), p = 0.059;
BMI > 30: 1.38 (0.93–
2.04), p = 0.11; T2DM:
2.00 (1.19–3.38), p =
0.009
Mod
Otgonsuren
2013 [34]
US (NHANES
III)
Prospective
population cohort,
10,565, age 20–50
years, 45% M
13.8 Yes
(ultrasound)
(exclusion of
other causes of
LD)
Obesity LD mortality, 26
events
Alcohol, BP,
T2DM
BMI > 30: 1.06 (0.96–
1.16), p = 0.25; WC:
1.02 (0.98–1.07), p =
0.332; WHR > 0.8:
83.51 (2.03–3,434.26),
p = 0.02
Low
Pang 2018
[35]
China (China
Kadoorie
Biobank)
Prospective
population cohort,
503,993, mean age
51.5 years, 41% M
10 No (exclusion
of other causes
of LD)
T2DM Cirrhosis/
complications,
2,082 events
Alcohol, BMI T2DM: 1.78 (1.45–
2.18), p< 0.001
Mod
(Continued)
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analysis as insufficient data were presented to support calculation of confidence intervals
around the adjusted effect measure [39]. Overall, in the 12 observational studies, there were
22.8 million individuals followed up for a median of 10 years (IQR 6.4–16.9) experiencing
72,792 fatal and/or non-fatal severe liver disease events. Most of the studies included middle-
Table 1. (Continued)
Study Country Study design and
population
Years of
follow-
up
Diagnosis of
NAFLD at
cohort
inclusion
Metabolic
RFs studied
Study outcomes
of interest and
number of events
Adjustments of
interest
considered
Adjusted HRs for
liver events with 95%
CIs and p-values
Risk
of
bias
Porepa 2010
[36]
Canada Retrospective data
linkage cohort
analysis, 2,497,777,
mean age 55.3
years, 56.3% M
6.4 No (exclusion
of other causes
of LD)
T2DM, BP,
obesity
Cirrhosis/
complications,
8,365 events
BP, lipids,
obesity, T2DM
T2DM: 1.77 (1.68–
1.86), p< 0.001; high
BP: 1.23 (1.14–1.31), p
< 0.001; BMI > 30:
1.16 (1.01–1.33),
p = 0.03
Low
Schult 2011
[37]
Sweden
(Gothenberg
survey)
Prospective
population cohort,
855, mean age 50
years,100% M
40 No (exclusion
of other causes
of LD)
All
metabolic
risk factors
Composite non-
fatal and fatal LD,
14 events
Alcohol BMI > 30: 1.27 (1.09–
1.48), p = 0.002;
triglycerides: 1.99
(1.35–2.96), p = 0.001;
other HRs not
presented
Mod
Schult 2018
[38]
Sweden
(Gothenberg
survey)
Prospective
population cohort,
1,462, age 38–60
years, 100% F
42 No (exclusion
of other causes
of LD)
Obesity
(central)
Composite non-
fatal and fatal LD,
11 events
Alcohol, BP WHR > 0.8: 5.82
(1.59–21.4), p = 0.008
Mod
Simeone
2017 [39]
US Retrospective data
linkage cohort
analysis, 18,754,
age > 18 years,
38.5% M
2.3 Yes (coding)
(exclusion of
other causes of
LD)
T2DM Composite non-
fatal and fatal LD,
5,645 events (any
disease
progression)
Unclear T2DM: 2.0 (no CI
given)
High
Stepanova
2010 [40]
US (NHANES
III)
Prospective
population cohort,
991, age > 17 years,
47.5% M
13.3 Yes (abnormal
blood tests)
(exclusion of
other causes of
LD)
All
metabolic
risk factors
LD mortality, 117
events
Alcohol, other
metabolic RFs
T2DM: 1.05 (1–1.65),
p< 0.05@; high
cholesterol: 0.37
(0.06–2.15), p = 0.284;
high BP: 0.07 (0.01–
0.3x), p = 0.007;
BMI > 30: 11.19
(2.43–51.56), p =
0.002; MS: 12.08
(1.10–132.22), p =
0.042
Mod
Younossi
2013 [41]
US (NHANES
III)
Prospective
population cohort,
1,448, age > 18
years, 64% M
16 Yes
(ultrasound)
(exclusion of
other causes of
LD)
Metabolic
syndrome,
obesity
LD mortality, 10
events
Metabolic RFs,
alcohol
BMI > 30: 1.12 (1.03–
1.21), p = 0.008; MS:
294.24 (118.74–
729.14), p< 0.001
Low
BMI units are kg/m2.
�Adjusted HR for whole cohort using a fixed-effects meta-analysis to get the combined HR from the 2 presented HRs for subgroups (coded versus uncoded combined in
Alexander et al.; men and women combined in Andreasson et al.).
$Sub-cohort of the 2018 Hagstro¨m study but with additional data on alcohol consumption.
@CI and p-value as given in the paper presented here—different from the calculated CI used in meta-analysis using the HR and sample size (Fig 2). This difference is due
to CI asymmetry in the published figures and inability to reproduce these figures on log transformation. Authors contacted to confirm data—no response.
BMI, body mass index; BP, blood pressure; CI, confidence interval; F, female; HDL, high-density lipoprotein; HR, hazard ratio; LD, liver disease; M, male; mod,
moderate; MS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; RF, risk factor; T2DM, type 2 diabetes mellitus; WHR, waist-to-hip ratio; WC, waist
circumference.
https://doi.org/10.1371/journal.pmed.1003100.t001
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aged individuals, with 7 studies including male and female individuals in roughly equal num-
bers, 2 studies including only women, and 3 only/predominantly men.
The individual study and pooled estimates of the association between T2DM and risk of
severe liver disease are shown in Fig 2. T2DM was significantly associated with an increased
risk of severe liver disease events (random-effects HR 2.25, 95% CI 1.83–2.76, p< 0.001, I2
99%). There was no asymmetry of the funnel plot to suggest a publication bias (S1 Fig).
Obesity and the risk of incident severe liver disease events
Fourteen studies were included in the meta-analysis of obesity as a prognostic factor for inci-
dent severe liver disease. The definition of obesity used for the meta-analysis was a BMI> 30
kg/m2 as this was the most widely reported metric used. Some of the included studies, and oth-
ers, also looked at alternative measures of obesity risk, such as waist-to-hip ratio (WHR).
There were too few studies to pool these results, but the findings are reported in the narrative
synthesis below. The 14 observational studies in the meta-analysis provided data on 19.3 mil-
lion individuals followed up for a median of 13.8 years (IQR 9.0 to 19.8) experiencing 49,541
fatal and/or non-fatal severe liver disease events. Nine of the studies of predominantly middle-
aged individuals included men and women in roughly equal numbers. Two studies looked at
women only, with 1 of the cohorts recruiting women in the early stages of pregnancy only
[28]. The 3 remaining studies recruited predominantly men—1 at army conscription (ages 18–
20 years), producing a younger study population at baseline, with follow-up for nearly 40 years
[26].
Fig 2. Random-effects meta-analysis of the risk of incident severe liver disease associated with type 2 diabetes. Statistical test for study
heterogeneity = chi-squared test. Statistical test for summary effect in the meta-analysis = Z test. IV, inverse variance.
https://doi.org/10.1371/journal.pmed.1003100.g002
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The individual and pooled estimates of association between obesity (BMI > 30 kg/m2) and
risk of severe liver disease are shown in Fig 3. A BMI > 30 kg/m2 was associated with an
increased risk of severe liver disease events (random-effects HR 1.20, 95% CI 1.12–1.28, p<
0.001, I2 87%). There was some asymmetry of the funnel plot, suggesting possible under-pub-
lishing of smaller negative studies (S2 Fig).
Sensitivity analyses
Limiting the analysis to studies judged to be at low risk of bias and excluding studies where
NAFLD was diagnosed at cohort entry provided overall estimates consistent with the primary
analysis for both prognostic factors that were meta-analysed (Table 2). The high levels of het-
erogeneity, as indicated by the high I2 values, were explored. These were felt to be due to the
variation in study design, particularly around the range of populations and outcomes studied,
leading to clinical heterogeneity. Despite this, there was a consistent direction of effect, and,
based on the objective of the review, pooling using meta-analysis was still felt to be
appropriate.
Other measures of central obesity
Four studies looked at alternative measures of central obesity as possible prognostic factors for
severe liver disease outcomes. One prospective cohort examined the subscapular-to-triceps
Fig 3. Random-effects meta-analysis of the risk of incident severe liver disease associated with obesity (BMI> 30 kg/m2). Statistical test
for study heterogeneity = chi-squared test. Statistical test for summary effect in the meta-analysis = Z test. IV, inverse variance.
https://doi.org/10.1371/journal.pmed.1003100.g003
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skinfold thickness ratio (SFR) as a measure of central obesity [30], concluding that in obese
individuals (BMI> 30 kg/m2), only those with a SFR> 1 were at increased risk of a combined
fatal/non-fatal severe liver disease outcome (HR 2.2, 95% CI 1.1–4.6, p = 0.026). Two studies
reported the association between waist circumference (WC) and liver disease events [21,34],
with 1 of the studies (using a combined fatal/non-fatal endpoint) reporting that a WC over 88
cm in women was a better predictor of liver outcomes than BMI (HR for BMI > 30 kg/m2: 1.3,
95% CI 0.4–1.88, p = 0.16; HR for WC> 88: 1.75, 95% CI 1.32–2.33, p< 0.001), but that this
was not the case for men [21]. The other study found no significant association between WC
and liver disease deaths, but did not stratify results by sex [34]. Two studies analysed the rela-
tionship between WHR and severe liver disease outcomes. One study focused on women and,
using a combined fatal/non-fatal endpoint, found a strong association between a WHR > 0.8
and severe liver disease (HR 5.82, 95% CI 1.59–21.4, p = 0.008). Only a small number of the
nearly 1,500 cohort participants had diabetes recorded at cohort entry (n = 13), and no inci-
dent diabetes was recorded during follow-up. The lack of meaningful adjustment for diabetes
was felt to be a study weakness [38]. The other study reporting WHR as a prognostic factor
again found this central obesity measure to prognosticate better than BMI in women only,
with the HR being nearly identical to that for BMI> 30 kg/m2 in men. For women, the HR
was 2.05 (95% CI 1.49–2.82, p< 0.001) for those with a WHR more than 0.05 above normal
[21]. There were insufficient similar studies to be able to pool any of the results, but the avail-
able data suggest that measures of central obesity are better at prognosticating for severe liver
disease outcomes than BMI alone, particularly in women.
Other metabolic risk factors and the risk of severe liver disease events
Lipids. Five studies investigating lipid levels, and their prognostic value for liver disease
outcomes, looked at low high-density lipoprotein (HDL), high triglycerides, combined lipid
abnormalities, and hypercholesterolaemia as exposures of interest, with varying cutoff points
for ‘abnormality’, so direct comparison and pooling was not attempted. By far the largest study
that looked at low HDL and high triglycerides as independent risk factors, in line with cutoffs
for a diagnosis of metabolic syndrome, examined an unselected population of over 100,000.
This study reported a HR for a non-fatal severe liver disease event of 1.28 for low HDL (95%
CI 1.04–1.59, p = 0.02) and 1.30 for high triglycerides (95% CI 0.99–1.72, p = 0.059�; analysis
done on a smaller dataset of 65,000 with available complete data) [33]. A large population-
based data linkage study of over 270,000 individuals (over 95% male) supports these findings,
with a reported HR of 1.23 (95% CI 1.19–1.28, p< 0.001) for an outcome of cirrhosis using a
combined dyslipidaemia exposure based on low HDL and/or high triglycerides [31]. This sug-
gests a smaller adjusted effect of these metabolic risk factors compared to the effect of T2DM,
perhaps similar to the adjusted effect of a BMI> 30 kg/m2, but is based on few studies.
Table 2. Risk of fatal and/or non-fatal severe liver disease events associated with T2DM and obesity: Sensitivity analyses.
Analysis Number of comparisons Overall adjusted HR with 95% CI I2 value
T2DM and risk of severe liver disease
Including only those with no previous diagnosis of NAFLD at cohort entry 10 2.54 (2.19–2.94), p< 0.001 96%
Including only studies with low risk of bias using QUIPS tool 8 2.59 (1.99–3.36), p< 0.001 99%
BMI > 30 kg/m2 and risk of severe liver disease
Including only those with no previous diagnosis of NAFLD at cohort entry 11 1.29 (1.14–1.46), p< 0.001 87%
Including only studies with low risk of bias using QUIPS tool 10 1.18 (1.10–1.26), p< 0.001 89%
CI, confidence interval; HR, hazard ratio; NAFLD, non-alcoholic fatty liver disease; QUIPS, Quality in Prognosis Studies; T2DM, type 2 diabetes mellitus.
https://doi.org/10.1371/journal.pmed.1003100.t002
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Hypertension. Four studies reported on hypertension as a prognostic factor of interest in
predicting severe liver outcomes. A mortality study looking at individuals with presumed
NAFLD (based on abnormal liver blood tests) found a negative association after adjustment
for other metabolic risk factors (HR 0.07, 95% CI 0.01–0.3, p = 0.007) [40]. This is contradicted
by 2 larger population-based data linkage studies looking at non-fatal severe liver disease,
which both report a positive association between diagnosed hypertension and an incident liver
outcome with HRs of 1.23 (95% CI 1.14–1.31, p< 0.001) [36] and 1.59 (95% CI 1.51–1.69, p<
0.001) [31]. This association was supported, although with a much smaller effect size, by find-
ings of a study using several large European primary care datasets to report non-fatal liver out-
comes (HR 1.06, 95% CI 1.00–1.12, p = 0.03) [20].
Metabolic syndrome. Three articles reported on the association between metabolic syn-
drome (NCEP ATP III definition) [15] and liver mortality using data from the same population
cohort study [25,40,41], with 1 additional study looking at combined metabolic risk with cirrhosis
as the outcome [31]. The effect sizes in the mortality data are inconsistent, with very wide confi-
dence intervals, despite the studies representing the same population. One of the studies reported
a weakening of the association of metabolic risk factors with liver-related mortality with increasing
number of metabolic risk factors [25]. The other 2 analyses concluded that metabolic syndrome
(�3 metabolic risk factors) was associated with an increased risk of liver-related mortality, with
reported HRs of 12.08 (95% CI 1.10–132.22, p = 0.042) [40] and 294.24 (95% CI 118.74–729.14, p
< 0.001) [41]. A more recent, larger population data linkage study looked in detail at combina-
tions and numbers of metabolic risk factors associated with cirrhosis outcomes, reporting increas-
ing HRs for increasing numbers of risk factors, with a HR of 2.56 (95% CI 2.26–2.92, p< 0.001)
for those with T2DM, obesity, hypertension, and dyslipidaemia [31].
Discussion
In this systematic review and meta-analysis of 22 studies including data from over 24 million
individuals, we found that T2DM was significantly associated with incident severe liver dis-
ease, with a more than 2-fold increase in the combined outcomes studied (random-effects HR
2.25, 95% CI 1.83–2.76, p< 0.001, I2 99%). There was a less marked association between obe-
sity and incident severe liver disease using BMI> 30 kg/m2 as the obesity measure (random-
effects HR 1.20, 95% CI 1.12–1.28, p< 0.001, I2 87%), with a suggestion that other measures of
central adiposity may better predict poor liver outcomes, particularly in women.
There were many fewer studies looking at the relationship between other metabolic risk fac-
tors and incident severe liver disease, with differing definitions of prognostic factors of inter-
est. Pooling of results was therefore not appropriate, but the suggestion from the largest,
highest quality studies was that lipid abnormalities (low HDL and high triglycerides) and
hypertension are both independently associated with incident severe liver disease. The
adjusted effect sizes appear to be similar to that for high BMI. Fewer data were available look-
ing at combinations of metabolic risk factors making up the metabolic syndrome as a predictor
of liver outcomes, with a suggestion from the largest study of an increase in non-fatal liver out-
comes in those with metabolic syndrome of a similar magnitude to that for T2DM.
The presented review focuses on general population data, aiming for the results to be appli-
cable for clinicians seeing unselected patients. Studies of individuals with biopsy-proven
NAFLD at cohort entry have been criticised due to the inherent bias of selecting patients who
have been referred for liver biopsy, and the relatively short median follow-up time. These stud-
ies, however, provide important comparative and supportive evidence.
Studies looking at metabolic risk factors in patients with biopsy-proven NAFLD and long-
term severe liver disease outcomes have found strong independent associations between
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T2DM at the time of biopsy and liver-related outcomes [4,41–43]. HRs for T2DM as a predic-
tor of severe outcomes in these studies vary more widely, partly due to the inclusion of all-
cause mortality in some of the studies, where the commonest cause of death was cardiovascular
disease rather than liver-related mortality. Studies specifically reporting liver-related outcomes
clearly report T2DM as the most important clinical risk factor, reporting HRs between 2.19
(95% CI 1.00–4.81) [43] and 22.83 (95% CI 2.97–175.03) [44] for liver-related mortality. These
studies generally do not report other metabolic risk factors as independent predictors of poor
outcome, although smaller sample sizes may indicate they were not powered adequately to
detect these smaller risk increases.
A significant body of related research has come from paired sequential liver biopsy studies
looking at the association between metabolic risk factors and histological NAFLD progression.
A systematic review of 11 paired biopsy studies (411 individuals) published in 2015 indicated
that only hypertension was significant in predicting the rate of histological progression
between biopsies (odds ratio 1.94, 95% CI 1.00–3.74) [45]. In line with our findings, more
recent studies, including the largest single-centre biopsy cohort to date, identified T2DM as
the strongest metabolic predictor of histological disease progression [46,47].
A large body of work has been extensively reviewed and synthesised on the epidemiology
and natural history of NAFLD. The focus of these reviews is distinct yet complementary to our
work. They identify the high and rising global burden of NAFLD and associated adverse out-
comes using prevalence data from cross-sectional studies of people with a confirmed diagnosis
of NAFLD. These reviews estimate the global prevalence of NAFLD in people with diabetes to
be more than double that of the general population (55.48% versus 25.2%) [1,48,49]. A recent
meta-analysis looking at NAFLD in T2DM reported prevalence estimates for NASH of 37.3%
and advanced fibrosis of 17% in those with T2DM, far higher than general population esti-
mates of these progressive forms of NAFLD [49]. This review adds to these prevalence data,
indicating that the rate of incident severe liver outcomes is also significantly higher in those
with T2DM.
It is noteworthy that despite our outcome inclusion criteria including NASH and advanced
fibrosis, none of the included studies reported these earlier disease stages as outcomes. This
leaves information on the association between metabolic risk and NASH/advanced fibrosis
coming from cross-sectional and highly selected populations [48]. As NASH and advanced
fibrosis have traditionally been histological diagnoses requiring a liver biopsy, this is not sur-
prising and may explain the paucity of evidence reported in a similar review of the ability of
NAFLD risk factors to predict progressive disease in the population [12].
In this synthesis we included data from population cohorts without a definite clinical
diagnosis of NAFLD at baseline. It is therefore possible that not all liver outcomes in these
groups were due to underlying NAFLD, which is a study limitation. All included studies
reported that people with known liver disease of other common aetiologies (which would
include viral hepatitis) were excluded and have adjusted for alcohol in the analysis. However,
the possibility of other undiagnosed pathologies cannot be fully excluded. A recent multi-site
European cohort study found that metabolic risk factors predicted cirrhosis with similar effect
sizes for people with and without a coded diagnosis of NAFLD [20] and suggested this was
likely due to NAFLD not being diagnosed or accurately coded (i.e., hidden disease in the con-
trol group). Other studies have also reported lower than expected levels of diagnostic coding
for NAFLD [50]. This suggests that our approach may be a strength, as only a minority of peo-
ple living with NAFLD have had a formal diagnosis, and so represent a highly selected
subgroup.
The limitations of synthesising observational data, including the issue of unmeasured con-
founding, are well known, and the clinical and statistical heterogeneity described in this review
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was not unexpected. We also acknowledge the possibility of publication bias. However, this
was a large study, including data on over 24 million individuals with over 300 million person
years of follow-up. Use of predetermined inclusion and exclusion criteria and robust quality
assessment mean we have included the best available evidence to report on the outcome of
incident advanced liver disease related to metabolic risk.
Identifying those at risk of severe liver disease in the community setting will only be benefi-
cial if effective lifestyle interventions and/or liver-targeted medications are effective and avail-
able. We have increasing evidence for the clinical effectiveness of lifestyle interventions in
NAFLD [51,52], 1 compound already has demonstrated efficacy in a phase III trial [53], and
several other promising liver-targeted medications are also in phase III studies [54]. There is
also an increasing evidence base around the cost-effectiveness of earlier case finding in the
community setting [11,55]. These advances highlight the timely nature of this review, which
can help guide clinicians and primary care policy-makers towards selecting the patients most
likely to benefit from these interventions. Future research should focus on studying prospec-
tive population cohorts for earlier liver outcomes and their relationship to metabolic risk,
including the interplay of these risk factors in combination. With increased availability of non-
invasive methods to look for advanced fibrosis, looking at earlier outcomes will become both
more realistic for research studies and, more importantly, more relevant for clinicians manag-
ing unselected populations who are looking to target, diagnose, and manage those at increased
risk of poor outcomes before they develop decompensated cirrhosis.
In conclusion, this robust meta-analysis provides evidence to suggest that people with
T2DM have a significantly increased risk of future severe liver disease and that obesity (as mea-
sured by BMI) also has an impact on risk. More evidence is needed around the interplay of
metabolic risk factors (metabolic syndrome) in predicting severe liver outcomes in people at
risk of NAFLD. Our findings support a more structured, risk-factor-based approach in
NAFLD management, particularly for patients with T2DM.
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